Please ensure Javascript is enabled for purposes of website accessibility

Analyst: Trulieve Stock Could Double and Then Some

By Eric Volkman - Apr 30, 2021 at 7:38PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company has immense potential both inside and outside of its home state of Florida believes one high-profile prognosticator.

Trulieve Cannabis (TCNNF -0.21%), the relatively successful Florida-based marijuana company, was an investor favorite Friday. That was due in no small part to a glowing new research note from noted pot industry analyst Pablo Zuanic of Cantor Fitzgerald. In his analysis, Zuanic raised his price target to $89 per share -- a stunning 114% higher than the company's most recent closing stock price.

It almost goes without saying that the prognosticator is maintaining his overweight (buy, in other words) recommendation on Trulieve stock.

A $100 bill with marijuana leaf atop it.

Image source: Getty Images.

Although Trulieve is known, and celebrated, for effectively defending its powerful market position in its native Florida, Zuanic is particularly encouraged by the company's expanding presence in other states. He believes, meanwhile, that Florida is a market that still has a lot of potential.

"While the company's FL [sequential volume] growth may have decelerated by 2-3[%], [company] sales there should still be up at least mid-teens ([roughly] $180 [million])," he wrote.

"Also, [Pennsylvania] will contribute a full [quarter] in 1Q21 (Pitt deal closed 11/12). In the year ahead, Trulieve will also get the benefit of starting sales in [Massachusetts], the Philly deal closing in 2Q, besides ongoing underlying growth in the established FL business... While much smaller, sales in [Connecticut], [California], and [West Virginia] will round the overall picture." Zuanic added.

In the Pennsylvania market, the analyst was referring to a set of recent Trulieve deals in which the company bought dispensary assets in the big Mid-Atlantic state.

Trulieve indeed has excellent potential outside of its home market, particularly if Pennsylvania eventually goes the way of big neighbors New York and New Jersey by legalizing recreational pot (at present, only medical consumption and use is permitted). The company's stock shot 5.7% higher Friday, while the S&P 500 index slumped by 0.7%.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Trulieve Cannabis Stock Quote
Trulieve Cannabis
$11.49 (-0.21%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.